CHARACTERISATION OF CHEMSEX IN PREP USERS IN FOUR HOSPITALS OF BUENOS AIRES, ARGENTINA

Zorz, Maria Belen 1; Pastor, Isabel 1; Kundro, Mariana Angelica 1; Viloria, Guillermo Alberto 1; Alonso Serena, Marina 1; Cardozo, Federico 1; Cecchini, Diego 2; Barletta, Jose 3; Altclas, Iael 4; Losso, Marcelo Horacio 1

1 Emergent diseases, Hospital General de Agudos José María Ramos Mejía, CABA, Buenos Aires, Argentina. 2. Infectious diseases, Hospital General de Agudos Dr. Cosme Argerich, CABA, Buenos Aires, Argentina. 3. Infectious diseases, Hospital General de Agudos Dr. Juan A. Fernández, CABA, Buenos Aires, Argentina. 4. Infectious diseases, Hospital Donación Francisco Santojanni, CABA, Buenos Aires, Argentina.



HIV GLASGOW 2024

POSTER NUMBER: P239

BACKGROUND:

The practice of chemsex consists of the intentional use of substances to increase activity or sexual pleasure. This practice could be associated with high-risk sexual behaviors that can increase the transmission of sexually transmitted infections (STIs) as well as expose users to potentially severe adverse events related to the used drugs [1,2].

PrEP for HIV consists in the use of antiretroviral drugs to reduce the risk of infection. A history of having practiced chemsex was associated with a greater probability of having a diagnosis of STIs in PrEP users [3]. In Argentina there is limited information regarding this problem [4]. This research aims to measure the prevalence and characterize the practice of chemsex and STIs in PrEP users in four hospitals in the City of Buenos Aires, Argentina.

METHODS AND MATERIAL:

This is a descriptive, cross-sectional study. The medical records and a self-administer questionnaire were used to obtain the information. Descriptive statistics and the χ^2 or the Mann–Whitney test were used to compare categorical and continuous variables, respectively.

RESULTS:

From February to June 2024, **108 PrEP users were included**, the study is still enrolling and here we report preliminary results. The median age was 34 years (IQR 30-40). 94% identified as cisgender men.

The median days in PrEP and the prevalence of STIs in the last year were, for chemsex users and not users respectively: 628 (IQR 525-813) vs. 486 days (IQR 224-715) and 52 vs. 37 % (Table 1).

In the last 12 months, **53% practiced chemsex**, the drugs used were: cocaine, 35%; MDMA (ecstasy), 33%; ketamine, 23%; γ-hydroxybutyrate (GHB), 21%; Methamphetamine, 10%; γ-butyrolactone (GBL), 3% and mephedrone, 3% (Fig. 1). **40%** reported **use of two or more drugs at the same time**,

21% recognized chemsex as a problem in their life.





n (%)	29 (52 %)	19 (37 %)	0.13	
Number of sexual partners in the last year, median (IQR)	20 (12-50)	20 (8-37)	-	

CONCLUSIONS:

We have identified a high prevalence of chemsex in PrEP users in Buenos Aires, Argentina. This highlights the need to take into consideration this topic in the development of PrEP and sexual health strategies.

REFERENCES

1. Strong C, Huang P, Li CW, Ku SW, Wu HJ, Bourne A. HIV, chemsex, and the need for harm-reduction interventions to support gay, bisexual, and other men who have sex with men. Lancet HIV. 2022 Oct;9(10):e717-e725. doi: 10.1016/S2352-3018(22)00124-2. Epub 2022 Aug 1. PMID: 35926550

2. McCall H, Adams N, Mason D, Willis J. What is chemsex and why does it matter? BMJ. 2015 Nov 3;351:h5790. doi: 10.1136/bmj.h5790. PMID: 26537832.

3. MacGregor L, Kohli M, Looker KJ, et al Chemsex and diagnoses of syphilis, gonorrhoea and chlamydia among men who have sex with men in the UK: a multivariable prediction model using causal inference methodology. Sexually Transmitted Infections 2021;97:282-289.

4. Salusso D, Nuñez S, Cabrini M, et al. Chemsex y uso de sustancias durante las relaciones sexuales: resultados de una encuesta realizada en Argentina. Actualizaciones en sida e infectología. Buenos Aires. Noviembre de 2020. volumen 28. número 103: 40-50.